Acute myeloid leukemia in the elderly: Current therapeutic results and perspectives for clinical research

Felicetto Ferrara, Antonio Pinto

Research output: Contribution to journalArticle

Abstract

More than half of acute myeloid leukemia (AML) diagnoses are currently made in patients older than 60 years. Furthermore, even if the age-specific incidence remains stable in the coming years, the incidence of AML in elderly people is expected to consistently increase, given the progressive ageing of the general population. Consequently, the treatment of the disease in aged individuals represents a daily challenge in clinical hematology. Several studies have shown that, in current practice, a high fraction of patients older than 60 years is negatively selected for inclusion in clinical trials that are based on intensive chemotherapy. Apart from performance status and comorbidity at diagnosis, other non-clinical factors can significantly affect therapeutic choice including the distance from hematologic institution, presence of a carer, physician's and patient's attitude, and the scientific interest of the physician in a given therapeutic programme. In daily practice, a combination of these factors results in relevant selection of patients for clinical trials. Clearly, preselection of patients with AAC leads to misleading overly optimistic results in some studies. Treatment of AML in the elderly is difficult and well-controlled trials in this group of patients are uncommon. Frequently, higly selected patients are recruited to relatively small phase II unrandomised trials with complete remission (CR) rates ranging from 25 to 70 %. These figures may turn unrealistic in the current practice. The present article reviews results of most relevant studies addressing therapeutic results in elderly patients with AML. Questions to be addressed will include potential selection biases, results with conventional chemotherapy, the therapeutic potential of autologous and allogeneic stem cell transplantation and a critical review of results achieved with newly developed drugs.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalReviews on Recent Clinical Trials
Volume2
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Acute Myeloid Leukemia
Research
Therapeutics
Clinical Trials
Physicians
Drug Therapy
Selection Bias
Incidence
Stem Cell Transplantation
Hematology
Patient Selection
Caregivers
Comorbidity
Pharmaceutical Preparations
Population

Keywords

  • Acute myeloid leukemia
  • Elderly patients
  • New drugs

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Acute myeloid leukemia in the elderly : Current therapeutic results and perspectives for clinical research. / Ferrara, Felicetto; Pinto, Antonio.

In: Reviews on Recent Clinical Trials, Vol. 2, No. 1, 01.2007, p. 33-41.

Research output: Contribution to journalArticle

@article{278d634809ac45b69c3757f4f36c9a57,
title = "Acute myeloid leukemia in the elderly: Current therapeutic results and perspectives for clinical research",
abstract = "More than half of acute myeloid leukemia (AML) diagnoses are currently made in patients older than 60 years. Furthermore, even if the age-specific incidence remains stable in the coming years, the incidence of AML in elderly people is expected to consistently increase, given the progressive ageing of the general population. Consequently, the treatment of the disease in aged individuals represents a daily challenge in clinical hematology. Several studies have shown that, in current practice, a high fraction of patients older than 60 years is negatively selected for inclusion in clinical trials that are based on intensive chemotherapy. Apart from performance status and comorbidity at diagnosis, other non-clinical factors can significantly affect therapeutic choice including the distance from hematologic institution, presence of a carer, physician's and patient's attitude, and the scientific interest of the physician in a given therapeutic programme. In daily practice, a combination of these factors results in relevant selection of patients for clinical trials. Clearly, preselection of patients with AAC leads to misleading overly optimistic results in some studies. Treatment of AML in the elderly is difficult and well-controlled trials in this group of patients are uncommon. Frequently, higly selected patients are recruited to relatively small phase II unrandomised trials with complete remission (CR) rates ranging from 25 to 70 {\%}. These figures may turn unrealistic in the current practice. The present article reviews results of most relevant studies addressing therapeutic results in elderly patients with AML. Questions to be addressed will include potential selection biases, results with conventional chemotherapy, the therapeutic potential of autologous and allogeneic stem cell transplantation and a critical review of results achieved with newly developed drugs.",
keywords = "Acute myeloid leukemia, Elderly patients, New drugs",
author = "Felicetto Ferrara and Antonio Pinto",
year = "2007",
month = "1",
doi = "10.2174/157488707779318099",
language = "English",
volume = "2",
pages = "33--41",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Acute myeloid leukemia in the elderly

T2 - Current therapeutic results and perspectives for clinical research

AU - Ferrara, Felicetto

AU - Pinto, Antonio

PY - 2007/1

Y1 - 2007/1

N2 - More than half of acute myeloid leukemia (AML) diagnoses are currently made in patients older than 60 years. Furthermore, even if the age-specific incidence remains stable in the coming years, the incidence of AML in elderly people is expected to consistently increase, given the progressive ageing of the general population. Consequently, the treatment of the disease in aged individuals represents a daily challenge in clinical hematology. Several studies have shown that, in current practice, a high fraction of patients older than 60 years is negatively selected for inclusion in clinical trials that are based on intensive chemotherapy. Apart from performance status and comorbidity at diagnosis, other non-clinical factors can significantly affect therapeutic choice including the distance from hematologic institution, presence of a carer, physician's and patient's attitude, and the scientific interest of the physician in a given therapeutic programme. In daily practice, a combination of these factors results in relevant selection of patients for clinical trials. Clearly, preselection of patients with AAC leads to misleading overly optimistic results in some studies. Treatment of AML in the elderly is difficult and well-controlled trials in this group of patients are uncommon. Frequently, higly selected patients are recruited to relatively small phase II unrandomised trials with complete remission (CR) rates ranging from 25 to 70 %. These figures may turn unrealistic in the current practice. The present article reviews results of most relevant studies addressing therapeutic results in elderly patients with AML. Questions to be addressed will include potential selection biases, results with conventional chemotherapy, the therapeutic potential of autologous and allogeneic stem cell transplantation and a critical review of results achieved with newly developed drugs.

AB - More than half of acute myeloid leukemia (AML) diagnoses are currently made in patients older than 60 years. Furthermore, even if the age-specific incidence remains stable in the coming years, the incidence of AML in elderly people is expected to consistently increase, given the progressive ageing of the general population. Consequently, the treatment of the disease in aged individuals represents a daily challenge in clinical hematology. Several studies have shown that, in current practice, a high fraction of patients older than 60 years is negatively selected for inclusion in clinical trials that are based on intensive chemotherapy. Apart from performance status and comorbidity at diagnosis, other non-clinical factors can significantly affect therapeutic choice including the distance from hematologic institution, presence of a carer, physician's and patient's attitude, and the scientific interest of the physician in a given therapeutic programme. In daily practice, a combination of these factors results in relevant selection of patients for clinical trials. Clearly, preselection of patients with AAC leads to misleading overly optimistic results in some studies. Treatment of AML in the elderly is difficult and well-controlled trials in this group of patients are uncommon. Frequently, higly selected patients are recruited to relatively small phase II unrandomised trials with complete remission (CR) rates ranging from 25 to 70 %. These figures may turn unrealistic in the current practice. The present article reviews results of most relevant studies addressing therapeutic results in elderly patients with AML. Questions to be addressed will include potential selection biases, results with conventional chemotherapy, the therapeutic potential of autologous and allogeneic stem cell transplantation and a critical review of results achieved with newly developed drugs.

KW - Acute myeloid leukemia

KW - Elderly patients

KW - New drugs

UR - http://www.scopus.com/inward/record.url?scp=34248382171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248382171&partnerID=8YFLogxK

U2 - 10.2174/157488707779318099

DO - 10.2174/157488707779318099

M3 - Article

C2 - 18473986

AN - SCOPUS:34248382171

VL - 2

SP - 33

EP - 41

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 1

ER -